Radiolabeled Thioflavin-T Derivative PET Imaging for the Assessment of Cardiac Amyloidosis

AbstractPurpose of ReviewCardiac amyloidosis (CA) is an often under-recognized cause of heart failure with preserved ejection fraction. The goal of the current paper was to review imaging modalities available for detecting cardiac amyloidosis. We wished to determine what modalities are available for the diagnosis of cardiac amyloidosis and what modalities could be utilized in the future.Recent FindingsEarly and delayed planar imaging of the chest currently plays a central role in the workup and diagnosis of CA. However, novel positron emission tomography (PET) tracers could play a large role in CA imaging in the future. There is an increasing body of literature supporting the use of targeted amyloid-binding PET radiotracers such as11C-Pittsburgh compound B (11C-PIB),18F-florbetapir, -flutemetamol, and -florbetaben for the detection of cardiac amyloid.SummaryWhile planar imaging currently plays a large role in the workup of CA, PET imaging could play an increasing important role in the future. The quantitative abilities of novel PET tracers could theoretically allow for the serial monitoring of patients and detection of response to therapy, and the sensitive nature of the tracers could allow for even earlier disease detection. Further work with large randomized controlled trial data is needed in the development and validation of PET tracers for cardiac amyloid and represents an exciting development within the realm of nuclear cardiology.
Source: Current Cardiology Reports - Category: Cardiology Source Type: research